For cancers that resist nearly every available treatment — glioblastoma, pancreatic ductal adenocarcinoma, metastatic castration-resistant prostate cancer — the therapeutic bottleneck often lies in redundant survival pathways that single-target drugs cannot simultaneously block. A new comprehensive review in the Journal of Experimental & Clinical Cancer Research makes a case that co-degrading two largely underexplored proteins, DDX5 and UbE2T, via a single small molecule may represent a meaningful advance in this space.

DDX5, an RNA helicase also designated p68, and UbE2T, a ubiquitin-conjugating enzyme, are characterized here as physically interacting partners with overlapping roles across DNA damage repair, topoisomerase regulation, and tumor microenvironment immune modulation. DDX5 is additionally implicated in EZH2- and NANOG-mediated prostate cancer stem cell programs that fuel neuroendocrine prostate cancer and treatment-refractory CRPC progression. The small molecule FL118 is presented as a dual molecular glue degrader — a mechanistic class that recruits an E3 ligase complex to simultaneously mark both proteins for proteasomal destruction. Preclinical data cited in the review demonstrate activity across colorectal cancer, PDAC, osteosarcoma, Ewing sarcoma, ovarian cancer, and glioblastoma models.

Molecular glue degraders have attracted intense pharmaceutical interest since the serendipitous characterization of thalidomide analogs as CRBN-dependent degraders, but purpose-designed dual-target glues remain rare. FL118's proposed mechanism — forced proximity degradation of two functionally linked oncoproteins — would, if validated in human trials, represent a notable step beyond conventional targeted monotherapy. That said, this article is a review and synthesis, not a report of new clinical data. The supporting evidence for FL118 derives from cell lines and animal models, where translational failure rates remain high. DDX5 has known roles in normal RNA processing, raising selectivity concerns not fully addressed here. Independent replication in clinical-stage studies will be essential before these findings carry actionable weight for patients or oncologists.